R13 (藥物)

R13
臨床資料
其他名稱	4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(methylcarbamate)
給藥途徑	口服給藥
藥物動力學數據
代謝產物	7,8-二羥基黃酮
識別資訊
	IUPAC命名法 [8-(Methylcarbamoyloxy)-4-oxo-2-phenylchromen-7-yl] N-methylcarbamate; ;
CAS號	1609067-49-3
PubChem CID	90117609;
UNII	OGG19T0LU2;
化學資訊
化學式	C19H16N2O6
摩爾質量	368.35 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CNC(=O)OC1=C(C2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)OC(=O)NC;
	InChI InChI=1S/C19H16N2O6/c1-20-18(23)26-14-9-8-12-13(22)10-15(11-6-4-3-5-7-11)25-16(12)17(14)27-19(24)21-2/h3-10H,1-2H3,(H,20,23)(H,21,24); Key:NWWRHMSYZTWUBD-UHFFFAOYSA-N;

參考文獻

^ ^1.0 ^1.1 ^1.2 Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Zhang Y, Ye K. The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. January 2018, 115 (3): 578–583. PMC 5777001  . PMID 29295929. doi:10.1073/pnas.1718683115  .
^ US application 20150274692,Keqiang Ye,「7,8-Dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto」,發表於2015-10-01,指定於Emory University